On January 25, 2012, Hoffmann-La Roche made an unsolicited bid to buy Illumina for $44.50 per share or about $5.7 billion [REF].
In late 2015, Illumina spun off the company Grail, focused on blood testing for cancer tumors in the bloodstream.